Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 178 for Amyloidosis

Edit search filters
  1. Experimental Antisense Oligonucleotide Treatment in AA Amyloidosis

    Rochester, MN

  2. Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

    Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, Rochester, MN

  3. Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

    Rochester, MN

  4. Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

    Rochester, MN

  5. MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

    Rochester, MN

  6. A Study to Evaluate MEDI2228 in Subjects with Relapsed/ Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

    Rochester, MN

  8. A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin amyloidosis

    Rochester, MN

  9. A Study of the Long-Term Safety of Tafamidis for Patients with Transthyretin Cardiomyopathy

    Rochester, MN

  10. A Study of the Long-Term Safety of Tafamidis in Subjects with Transthyretin Cardiomyopathy

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer